Trials / Completed
CompletedNCT00548691
Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 513 (actual)
- Sponsor
- American Regent, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The Objective of this study is to study the safety of FCM in patients with anemia caused by chronic kidney failure
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ferric Carboxymaltose | |
| DRUG | Standard Medical Care (SMC) |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2009-01-01
- Completion
- 2009-07-01
- First posted
- 2007-10-24
- Last updated
- 2018-02-20
- Results posted
- 2015-05-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00548691. Inclusion in this directory is not an endorsement.